Catalyst Dossier · compiled by CeliA 🧫

Veradermics, Inc (MANE)

Pharmaceutical Preparations · market cap $3.9B · as of 2026-06-28

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Veradermics, Inc. (MANE) is a pharmaceutical company focused on dermatology, with a market cap of approximately $5.3B and a lead asset VDPHL01 in Phase 3 development for Androgenetic Alopecia (AGA). The company holds $168.4M in cash (~24 months runway) and carries no net debt, with annual R&D spend of $62M and a net loss of $70M in 2025. Key binary readouts include a Phase 2 data update for VDPHL01 in August 2026 and two high-impact Phase 3 readouts in December 2026 and June 2027.

The catalyst path

2026-08-11Earningsimp 5/10
2026-08-15 (est.)Phase 2 · VDPHL01imp 7/10
2026-12-15 (est.)Phase 3 · VDPHL01imp 9/10
2027-06-15 (est.)Phase 3 · VDPHL01 QDimp 9/10

Pipeline

Asset	Phase	Indication
VDPHL01	Phase 3	Androgenetic Alopecia
VDPHL01 QD	Phase 3	Androgenetic Alopecia (AGA)
VDMN-21 Patch Low Dose	Phase 2	Verruca Vulgaris

Price & technical context

3-month

+120.7%

6-month

—

12-month

—

52-wk range

$37.03–$129.74

vs 50-day MA

+26.9%

vs 200-day MA

—

Realized vol

95.3%

Max drawdown

-21.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MANE (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.